New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
August 23, 2018 - The FDA announced the approval of Shire’s Takhzyro (lanadelumab-flyo), for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients 12 years and older.
Download PDF
Return to publications
